查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1955066

全球肿瘤PET（正子断层扫描）市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Oncology Positron Emission Tomography Scan Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 165 Pages | 商品交期: 请询问到货日

价格

肿瘤PET（正子断层扫描）市场成长驱动因子

2025年，全球肿瘤PET（正子断层扫描）市场规模为123.1亿美元。预计该市场将从2026年的130.3亿美元成长到2034年的206.6亿美元，在预测期（2026-2034年）内复合年增长率（CAGR）为5.93%。

2025年，北美在全球肿瘤PET扫描市场占主导地位，市场占有率达52.40%，这得益于其先进的诊断基础设施、较高的癌症发病率以及对创新成像技术的积极应用。技术。

肿瘤PET是一种非侵入性分子影像技术，广泛用于癌症的检测、分期、治疗效果评估和復发监测。全球癌症负担日益加重、对提高诊断准确性的需求不断增长、技术进步以及政府主导的癌症筛检计画是推动市场成长的关键因素。

市场动态

市场驱动因素

全球癌症负担日益加重是推动市场成长的主要因素。摄护腺癌、肺癌、乳癌和大肠癌发生率的上升，推动了扩大筛检计画和先进诊断工具的需求激增。各国政府和医疗系统正在大力投资早期检测措施，旨在降低死亡率和治疗成本。

例如，影像学指南的更新以及用于前列腺癌的新型PET造影剂的批准，正在加速PET扫描的普及。此外，对个人化医疗和早期诊断的日益重视，也正在加速肿瘤PET扫描在各种医疗机构中的应用。

市场限制因子

PET扫描器和检查的高成本仍然是主要的限制因素。 PET扫描仪的价格差异很大，从47.5万美元到超过75万美元不等，此外还需支付安装、维护、放射性示踪剂和专业技术人员的人工成本。

不一致的保险报销政策进一步限制了PET的普及，尤其是在发展中国家。即使在已开发市场，重复检查和特定肿瘤适应症的保险覆盖范围限制也阻碍了PET的推广应用，并对市场扩张产生负面影响。

市场机会

人工智慧（AI）与先进影像量化工具的结合带来了巨大的成长机会。 AI驱动的PET系统能够提高病灶侦测、肿瘤特性分析、工作流程效率和治疗效果评估的准确性。

持续的技术创新、人工智慧软体的监管批准以及下一代PET/CT系统的广泛应用预计将推动市场发展至2034年。

市场挑战

放射性示踪剂的供应和供应链限制是重大挑战。 FDG等放射性示踪剂的半衰期较短，需要高效率的物流和靠近迴旋加速器设施。延误和供应中断会导致患者等待时间延长和检查量减少，可能限制市场成长。

市场趋势

向治疗性诊断和个人化癌症影像的转型

影响市场的一个关键趋势是诊疗一体化技术的日益普及，该技术结合了诊断和标靶治疗。基于PET的诊疗一体化试剂，特别是用于前列腺癌的PSMA基示踪剂，能够实现精准诊断和即时治疗监测。

对个人化癌症影像和新型PET示踪剂研发的投资增加，正在改变癌症治疗管理，并推动市场长期成长。

新冠疫情的影响

由于封锁和供应链中断，新冠疫情严重扰乱了肿瘤PET服务。癌症筛检和诊断程序大幅下降，导致诊断延迟。

全球调查显示，2020年中PET扫描量下降超过65%，凸显了疫情的短期负面影响。然而，随着疫情后经济復苏和人们对癌症诊断的重新关注，市场动能正在恢復。

市场区隔分析

依资金来源划分

市场依资金来源分为公共医疗保险及私人医疗保险/自费支出。在美国、日本、印度和巴西等国家，由于就诊快速、医疗品质高、等待时间短，私人医疗机构占市场主导地位。

即使在公立医疗体系内，随着资金投入的增加和国家癌症控制计画的推进，PET扫描的普及程度也在不断提高。

依服务提供者划分

服务提供者包括医院、诊断中心等。

  • 预计到2025年，医院将占最大市场占有率，这得益于其先进的影像基础设施和熟练的医护人员。
  • 由于成本效益高、专业化程度高、等待时间短，诊断中心预计将实现最快成长。

区域展望

  • 北美市场引领市场，预计2025年市场规模将达到65亿美元，2026年将达到68.2亿美元，主要得益于高癌症发生率和技术的快速普及。
  • 欧洲占了相当大的市场占有率，这得益于其健全的医疗保健体系和不断增加的新型PET示踪剂的批准。
  • 亚太地区预计到2034年将实现最高的复合年增长率，主要得益于不断扩大的医疗基础设施和政府主导的各项举措。
  • 拉丁美洲以及中东和非洲地区预计将保持稳定成长，这主要归功于癌症发生率的上升和医疗保健投资的增加。

目录

第一章 引言

第二章 摘要整理

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章 主要发现

  • 主要国家癌症盛行率
  • 主要公司新产品发布
  • 主要产业发展动态（併购、业务合作等）
  • 肿瘤PET技术进步

第五章 全球肿瘤PET（正子断层扫描）市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依资金来源划分
    • 公共医疗保险/私人医疗保险/自付费用
  • 市场分析、洞察与预测：依服务提供者划分
    • 医院
    • 诊断中心
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美肿瘤PET（正子断层扫描）市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国州/省
    • 加拿大

第七章 欧洲肿瘤PET（正子断层扫描）市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区肿瘤PET（正子断层扫描）市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他亚洲国家太平洋

第九章 拉丁美洲肿瘤PET（正子断层扫描）市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章 中东与非洲肿瘤PET（正子断层扫描）市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲国家

第11章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
    • GE Healthcare
    • Sonic Healthcare Limited
    • Oncovision
    • Koninklijke Philips N.V.
    • Apex Radiology
    • Alliance Medical Limited
    • Novant Health
    • Canon Medical Systems
    • Dignity Health
    • Concord Medical
    • Siemens Healthcare Limited
    • Mediworks
    • Other Prominent Players
Product Code: FBI113540

Growth Factors of oncology positron emission tomography (PET) scan Market

The global oncology positron emission tomography (PET) scan market was valued at USD 12.31 billion in 2025. The market is projected to grow from USD 13.03 billion in 2026 to USD 20.66 billion by 2034, exhibiting a CAGR of 5.93% during the forecast period (2026-2034).

North America dominated the global oncology PET scan market with a 52.40% market share in 2025, supported by advanced diagnostic infrastructure, high cancer prevalence, and strong adoption of innovative imaging technologies.

Oncology PET is a non-invasive molecular imaging technique widely used for cancer detection, staging, therapy assessment, and recurrence monitoring. Rising global cancer burden, increasing demand for diagnostic accuracy, technological advancements, and government-led cancer screening programs are key factors driving market growth.

Market Dynamics

Market Drivers

The rising global burden of cancer is a primary driver of market growth. Increasing incidence of cancers such as prostate, lung, breast, and colorectal cancer has led to a surge in screening programs and demand for advanced diagnostic tools. Governments and healthcare systems are investing heavily in early detection initiatives to reduce mortality and treatment costs.

For instance, updated imaging guidelines and approvals of novel PET imaging agents for prostate cancer have strengthened PET adoption. Additionally, the growing emphasis on personalized medicine and early diagnosis is accelerating the use of oncology PET scans across healthcare settings.

Market Restraints

The high cost of PET scanners and procedures remains a significant restraint. PET scanners can cost between USD 475,000 and over USD 750,000, excluding expenses related to installation, maintenance, radiotracers, and skilled personnel.

Inconsistent reimbursement policies further limit accessibility, particularly in developing economies. Even in developed markets, limited insurance coverage for repeat scans and certain oncology indications restricts utilization, negatively impacting market expansion.

Market Opportunities

The integration of artificial intelligence (AI) and advanced image quantification tools presents a major growth opportunity. AI-enabled PET systems improve lesion detection, tumor characterization, workflow efficiency, and treatment response evaluation.

Continuous innovation, regulatory approvals of AI-based software, and growing adoption of next-generation PET/CT systems are expected to support market development through 2034.

Market Challenges

Radiotracer availability and supply chain constraints pose critical challenges. Radiotracers such as FDG have short half-lives, requiring efficient logistics and proximity to cyclotron facilities. Delays or disruptions can lead to longer patient wait times and reduced scan volumes, limiting market growth.

Market Trends

Shift Toward Theranostics and Personalized Oncology Imaging

A key trend shaping the market is the growing adoption of theranostics, which combines diagnostics and targeted therapy. PET-based theranostic agents, especially PSMA-based tracers for prostate cancer, enable precise diagnosis and real-time therapy monitoring.

Increasing investments in personalized oncology imaging and the development of novel PET tracers are transforming cancer management and driving long-term market growth.

Impact of COVID-19

The COVID-19 pandemic significantly disrupted oncology PET services due to lockdowns and supply chain interruptions. Cancer screening and diagnostic procedures declined sharply, leading to delayed diagnoses.

According to global surveys, PET scan volumes dropped by over 65% in mid-2020, highlighting the pandemic's negative short-term impact. However, post-pandemic recovery and renewed focus on cancer diagnostics have restored market momentum.

Segmentation Analysis

By Source of Payment

The market is segmented into public and private health insurance/out-of-pocket. The private segment dominated the market due to faster access, premium-quality care, and reduced waiting times, especially in countries such as the U.S., Japan, India, and Brazil.

Public healthcare systems are also expanding PET access through increased funding and national cancer control programs.

By Service Provider

Based on service providers, the market includes hospitals, diagnostic centers, and others.

  • Hospitals accounted for the largest share in 2025 due to advanced imaging infrastructure and skilled personnel.
  • Diagnostic centers are expected to register the fastest growth owing to cost efficiency, specialization, and shorter waiting periods.

Regional Outlook

  • North America led the market with USD 6.5 billion in 2025 and USD 6.82 billion in 2026, driven by high cancer prevalence and rapid technology adoption.
  • Europe held a substantial share due to strong healthcare systems and increasing approvals of novel PET tracers.
  • Asia Pacific is projected to record the highest CAGR through 2034, supported by healthcare infrastructure expansion and government initiatives.
  • Latin America and Middle East & Africa are expected to witness steady growth due to rising cancer incidence and improving healthcare investments.

Competitive Landscape

Key players operating in the global oncology PET scan market include GE Healthcare, Siemens Healthcare Limited, Oncovision, Koninklijke Philips N.V., Canon Medical Systems, and Sonic Healthcare Limited. These companies focus on product innovation, strategic collaborations, and regulatory approvals to strengthen their market presence.

Conclusion

The global oncology positron emission tomography scan market is set to grow steadily from USD 12.31 billion in 2025 to USD 20.66 billion by 2034, driven by the rising cancer burden, technological advancements, and increasing focus on personalized oncology imaging. While high equipment costs and radiotracer supply challenges remain key concerns, innovations in AI-enabled imaging, theranostics, and expanding screening programs are expected to sustain long-term market growth. North America will continue to dominate the market, while Asia Pacific is anticipated to emerge as the fastest-growing region during the forecast period.

Segmentation By Source of Payment

  • Public
  • Private Health Insurance/Out-of-pocket

By Service Providers

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America (By Source of Payment, Service Providers, and Country)
    • U.S.
    • Canada
  • Europe (By Source of Payment, Service Providers, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source of Payment, Service Providers, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Source of Payment, Service Providers, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Source of Payment, Service Providers, and Country/Sub-region)
    • GCC
    • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, Key Countries
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.4. Technological Advancements in Oncology PET

5. Global Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 5.1.1. Public
    • 5.1.2. Private Health Insurance/Out-of-pocket
  • 5.2. Market Analysis, Insights and Forecast - By Service Providers
    • 5.2.1. Hospitals
    • 5.2.2. Diagnostic Centers
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 6.1.1. Public
    • 6.1.2. Private Health Insurance/Out-of-pocket
  • 6.2. Market Analysis, Insights and Forecast - By Service Providers
    • 6.2.1. Hospitals
    • 6.2.2. Diagnostic Centers
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 7.1.1. Public
    • 7.1.2. Private Health Insurance/Out-of-pocket
  • 7.2. Market Analysis, Insights and Forecast - By Service Providers
    • 7.2.1. Hospitals
    • 7.2.2. Diagnostic Centers
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 8.1.1. Public
    • 8.1.2. Private Health Insurance/Out-of-pocket
  • 8.2. Market Analysis, Insights and Forecast - By Service Providers
    • 8.2.1. Hospitals
    • 8.2.2. Diagnostic Centers
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 9.1.1. Public
    • 9.1.2. Private Health Insurance/Out-of-pocket
  • 9.2. Market Analysis, Insights and Forecast - By Service Providers
    • 9.2.1. Hospitals
    • 9.2.2. Diagnostic Centers
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 10.1.1. Public
    • 10.1.2. Private Health Insurance/Out-of-pocket
  • 10.2. Market Analysis, Insights and Forecast - By Service Providers
    • 10.2.1. Hospitals
    • 10.2.2. Diagnostic Centers
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. GE Healthcare
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sonic Healthcare Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Oncovision
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Koninklijke Philips N.V.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Apex Radiology
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Alliance Medical Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Novant Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Canon Medical Systems
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Dignity Health
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Concord Medical
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Siemens Healthcare Limited
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Mediworks
      • 11.2.12.1. Overview
      • 11.2.12.2. Products
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. Other Prominent Players
      • 11.2.13.1. Overview
      • 11.2.13.2. Products
      • 11.2.13.3. SWOT Analysis
      • 11.2.13.4. Recent Developments
      • 11.2.13.5. Strategies
      • 11.2.13.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
  • Table 2: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
  • Table 3: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
  • Table 5: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
  • Table 6: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
  • Table 8: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
  • Table 9: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
  • Table 11: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
  • Table 12: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
  • Table 14: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
  • Table 15: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2021-2034
  • Table 17: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2021-2034
  • Table 18: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Oncology Positron Emission Tomography Scan Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025 & 2034
  • Figure 3: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025 & 2034
  • Figure 4: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Region, 2025 & 2034
  • Figure 5: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
  • Figure 6: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
  • Figure 7: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
  • Figure 8: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
  • Figure 9: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country, 2025
  • Figure 11: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
  • Figure 12: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
  • Figure 13: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
  • Figure 14: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
  • Figure 15: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
  • Figure 18: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
  • Figure 19: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
  • Figure 20: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
  • Figure 21: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
  • Figure 24: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
  • Figure 25: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
  • Figure 26: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
  • Figure 27: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2025 & 2034
  • Figure 30: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2025
  • Figure 31: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2025 & 2034
  • Figure 32: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2025
  • Figure 33: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Oncology Positron Emission Tomography Scan Market Share (%), By Company, 2025